The stock price of Aquestive Therapeutics Inc (NASDAQ: AQST) has jumped by 5.69 compared to previous close of 3.60. Despite this, the company has seen a fall of -0.39% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-09 that The ‘Undercovered’ Dozen series highlights 12 lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Xometry’s AI-driven procurement software in a specialized B2B marketplace shows high-growth potential to Bert Hochfeld, making it a promising investment. Grassroots Trading argues that Boston Scientific’s acquisition of Axonics enhances its urology offerings, positioning it strongly in the sacral neuromodulation field.
Is It Worth Investing in Aquestive Therapeutics Inc (NASDAQ: AQST) Right Now?
Moreover, the 36-month beta value for AQST is 2.67. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AQST is 77.61M and currently, short sellers hold a 13.08% of that float. On December 17, 2024, AQST’s average trading volume was 1.48M shares.
AQST’s Market Performance
The stock of Aquestive Therapeutics Inc (AQST) has seen a -0.39% decrease in the past week, with a -14.30% drop in the past month, and a -23.13% fall in the past quarter. The volatility ratio for the week is 4.44%, and the volatility levels for the past 30 days are at 6.02% for AQST. The simple moving average for the past 20 days is -12.33% for AQST’s stock, with a -6.02% simple moving average for the past 200 days.
Analysts’ Opinion of AQST
Leerink Partners, on the other hand, stated in their research note that they expect to see AQST reach a price target of $8. The rating they have provided for AQST stocks is “Outperform” according to the report published on May 10th, 2024.
Piper Sandler gave a rating of “Overweight” to AQST, setting the target price at $10 in the report published on April 11th of the current year.
AQST Trading at -20.37% from the 50-Day Moving Average
After a stumble in the market that brought AQST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.92% of loss for the given period.
Volatility was left at 6.02%, however, over the last 30 days, the volatility rate increased by 4.44%, as shares sank -18.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.86% lower at present.
During the last 5 trading sessions, AQST fell by -0.79%, which changed the moving average for the period of 200-days by -9.33% in comparison to the 20-day moving average, which settled at $4.34. In addition, Aquestive Therapeutics Inc saw 88.37% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AQST starting from Jung Cassie, who sale 44 shares at the price of $4.87 back on Nov 26 ’24. After this action, Jung Cassie now owns 0 shares of Aquestive Therapeutics Inc, valued at $214 using the latest closing price.
Schobel Alexander Mark, the Chief Innovation/Tech Officer of Aquestive Therapeutics Inc, sale 50,000 shares at $6.00 during a trade that took place back on Mar 15 ’24, which means that Schobel Alexander Mark is holding 984,476 shares at $300,000 based on the most recent closing price.
Stock Fundamentals for AQST
Current profitability levels for the company are sitting at:
- -0.36 for the present operating margin
- 0.69 for the gross margin
The net margin for Aquestive Therapeutics Inc stands at -0.6. The total capital return value is set at -0.22.
Based on Aquestive Therapeutics Inc (AQST), the company’s capital structure generated -2.21 points at debt to capital in total, while cash flow to debt ratio is standing at -1.09. The debt to equity ratio resting at -0.69. The interest coverage ratio of the stock is -1.33.
Currently, EBITDA for the company is 1.18 million with net debt to EBITDA at 2.09. When we switch over and look at the enterprise to sales, we see a ratio of 5.2. The receivables turnover for the company is 6.08for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.37.
Conclusion
To wrap up, the performance of Aquestive Therapeutics Inc (AQST) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
